Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Da: GRACEcast
0 0 7 anni fa
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

Seguici su Facebook